PATENT CLAIM ANALYSIS

Application Number: 15988947
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["536", "024500"]

Abstract:
The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer. Other aspects include methods of making and using such nanoparticles.

Claim (Index 11):
The pharmaceutically acceptable nanoparticle of  claim 10 , wherein the antibody targets a target selected from the group consisting of EpCAM (CD326), IGF-R, Mesothelin, Lewis-Y antigen (CD174), CanAg (MUC1, PEM, CA242, CD205), NCAM (CD56), Cripto, Melanotransferrin (P97), Glycoprotein NMB (CG56972), CD70 (CD27 Ligand), 5T4 (trophoblast glycoprotein), CD57, CD44, Carcinoembryonic antigen (CEA), GD2, CD40, Fibronectin ED-B, Endoglin (CD105), Tenascin C, Phosphatidylserine (PS), HER3, CD30, CD33, CD40, CD52, CD74, CD138, CS1 (CD319, CRACC), TAG-72, CD2, CD64, ROBO4, DLL4, Tie2, and B7-H3.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 93.0
- Lexical Diversity: 1.18519
- Patent Class: 536.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14656899', '15860881', '13910328', '15118737', '14091343']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6804941628397589
- 35 USC 102 Novelty (BERT): 0.5043809182186528
- Combined Prediction Score: 0.6628828383776484
- Mean Citation Score: 272.850088
- Max Citation Score: 282.66974
- Similarity Product: 197.2662979450584

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test